# Pharming Group N.V.: Form 20-F for the period ended Dec 31, 2021

- Company: [Pharming Group N.V.](/companies/phar.md) (CIK 1828316)
- Form: 20-F
- Filed: 2022-04-06
- Accepted by EDGAR: Apr 6, 2022, 16:07 ET
- Period: 2021-12-31
- Accession: 0001628280-22-008574
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1828316/000162828022008574/pharm-20211231.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1828316/000162828022008574/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2021-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 12 months, 2021-01-01 to 2021-12-31 | $198.9m | ifrs-full:RevenueFromContractsWithCustomers |
| Cost of revenue | 12 months, 2021-01-01 to 2021-12-31 | $21.1m | ifrs-full:CostOfSales |
| Gross profit | 12 months, 2021-01-01 to 2021-12-31 | $177.7m | ifrs-full:GrossProfit |
| Operating income | 12 months, 2021-01-01 to 2021-12-31 | $13.6m | ifrs-full:ProfitLossFromOperatingActivities |
| Income tax | 12 months, 2021-01-01 to 2021-12-31 | $7.1m | ifrs-full:IncomeTaxExpenseContinuingOperations |
| Net income | 12 months, 2021-01-01 to 2021-12-31 | $16.0m | ifrs-full:ProfitLoss |
| Diluted EPS | 12 months, 2021-01-01 to 2021-12-31 | $0.02 | ifrs-full:DilutedEarningsLossPerShare |
| Basic EPS | 12 months, 2021-01-01 to 2021-12-31 | $0.03 | ifrs-full:BasicEarningsLossPerShare |
| Operating cash flow | 12 months, 2021-01-01 to 2021-12-31 | $37.8m | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Capital expenditure | 12 months, 2021-01-01 to 2021-12-31 | $10.7m | ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| Cash and equivalents | at 2021-12-31 | $191.9m | ifrs-full:CashAndCashEquivalents |
| Current assets | at 2021-12-31 | $249.4m | ifrs-full:CurrentAssets |
| Total assets | at 2021-12-31 | $397.3m | ifrs-full:Assets |
| Current liabilities | at 2021-12-31 | $46.8m | ifrs-full:CurrentLiabilities |
| Shareholders' equity | at 2021-12-31 | $192.9m | ifrs-full:Equity |
| Shares outstanding | at 2021-12-31 | 648,749,000 shares | dei:EntityCommonStockSharesOutstanding |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1828316/000162828022008574/pharm-20211231.htm

Filed Apr 6, 2022.
Source: SEC EDGAR, the filing index for accession 0001628280-22-008574. Last ingested by Listed: Oct 27, 2026, 07:12 ET. No prices; not investment advice.